Moreover, identifying TP53 defects as early as possible during their evolution may represent a significant achievement in the clinical management of high-risk CLL, since TP53-deffective patients could be offered alternative treatment.1 The clinical impact of minor-proportion TP53 defects is currently a matter of debate.18, 26, 27 Their relevance for relapse development is supported by the actual number of mutated cells. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.